A small-molecule lead compound for the treatment of Alzheimer’s disease

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.2, 2005-02, pp. : 199-201

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Natural Products as Sources of New Lead Compounds for the Treatment of Alzheimer’s Disease

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 15, 2013-08 ,pp. : 1864-1878

Bentham Science Publishers

Access to resources Recommend Favorite

Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 – 2012)

By Belluti Federica Rampa Angela Gobbi Silvia Bisi Alessandra

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 5, 2013-05 ,pp. : 581-596

Informa Healthcare

Access to resources Recommend Favorite

Caffeine as a Lead Compound for the Design of Therapeutic Agents for the Treatment of Parkinson’s Disease

Current Medicinal Chemistry, Vol. 22, Iss. 8, 2015-03 ,pp. : 975-988

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacoeconomics of Cholinesterase Inhibitors in the Treatment of Alzheimers Disease

By Jönsson L.

PharmacoEconomics, Vol. 21, Iss. 14, 2003-01 ,pp. : 1025-1037

Adis International

Access to resources Recommend Favorite

Evaluation of memantine for the treatment of Alzheimer’s disease

By Ferris Steven H

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 12, 2003-12 ,pp. : 2305-2313

Informa Healthcare

Access to resources Recommend Favorite